Pharmaceutical - Respiratory and Pulmonary, USA

Filter

Popular Filters

1 to 25 of 29 results

Meda and Cipla sue Apotex to enforce Dymista patents

Meda and Cipla sue Apotex to enforce Dymista patents

04-12-2014

Swedish pharma company Meda Pharmaceuticals and Indian drugmaker Cipla today have sued Canada-headquartered…

ApotexCiplaDymistaLegalMedaPharmaceuticalRespiratory and PulmonaryUSA

Asthma drug market set to grow $23 billion by 2023

28-11-2014

The asthma treatment market value will grow across eight major countries (the USA, UK, France, Germany,…

AdvairAstraZenecaAustraliaEuropeGlaxoSmithKlineJapanMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicortUSA

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

16-10-2014

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech,…

Boehringer IngelheimEsbrietGenentechnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

30-09-2014

The US market for treatments of allergic rhinitis is set to see its value increase fourfold by 2018,…

GlobalDataGrastekMarkets & MarketingMerck & CoOralairPharmaceuticalRagwitekRespiratory and PulmonarySingulairUSA

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

25-09-2014

German family-owned pharma major Boehringer Ingelheim Pharmaceuticals has received US Food and Drug Administration…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivaUSA

FDA accepts Tuzistra XR NDA for full review

FDA accepts Tuzistra XR NDA for full review

15-09-2014

The US Food and Drug Administration has confirmed that the New Drug Application for Tuzistra XR, a prescription…

LicensingPharmaceuticalRegulationRespiratory and PulmonaryTris PharmaTuzistraUSAVernalis

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

US FDA backs approval of GSK’s Arnuity Ellipta for asthma

21-08-2014

UK pharma giant GlaxoSmithKline revealed late yesterday that the US Food and Drug Administration has…

Arnuity ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

15-08-2014

There was good news late yesterday for German family-owned pharma major Boehringer Ingelheim, when an…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivatiotropiumUS Food and Drug AdministrationUSA

Vertex received European approval for CF drug Kalydeco

Vertex received European approval for CF drug Kalydeco

01-08-2014

US biotech firm Vertex Pharmaceuticals has announced that the European Commission has approved Kalydeco…

BiotechnologyCommittee for Medicinal Products for Human UseCystic fibrosisKalydecoPharmaceuticalRegulationRespiratory and PulmonaryUSAVertex Pharmaceuticals

FDA approves Boehringer’s Striverdi Respimat for COPD

FDA approves Boehringer’s Striverdi Respimat for COPD

01-08-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimPharmaceuticalPulmonologyRegulationRespiratory and PulmonaryStriverdi RespimatUSA

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

GSK and Theravance submit US sNDA for Breo Ellipta in asthma

30-06-2014

US pharma giant GlaxoSmithKline and US partner Theravance have submitted a supplemental New Drug Application…

Breo ElliptaGlaxoSmithKlinePharmaceuticalRegulationRespiratory and PulmonaryTheravanceUSA

Vectura signs additional deal with unnamed US pharma company

Vectura signs additional deal with unnamed US pharma company

30-06-2014

UK developer of inhaled therapies Vectura Group has signed a US collaboration, development and license…

LicensingPharmaceuticalRespiratory and PulmonaryUKUSAVecturaVR315

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

Greer Labs debuts Oralair for the treatment of grass pollen allergy in USA

06-05-2014

USA-based allergy immunotherapy products and services specialist Greer Laboratories today announced the…

Ares Life SciencesGREER LaboratoriesMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenesUSA

US FDA approves GSK’s Incruse Ellipta for COPD

US FDA approves GSK’s Incruse Ellipta for COPD

01-05-2014

The US Food and Drug Administration has approved UK pharma major GlaxoSmithKline’s Incruse (umeclidinium)…

Chronic lower respiratory diseasesCOPDGlaxoSmithKlineIncruseIncruse ElliptaMajorMedicinePharmaceuticalPulmonologyRegulationRespiratory and PulmonaryUKUSA

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

Insmed’s mixed results from Ph II trial for treatment resistant NTM lung infections

27-03-2014

US-based Insmed has reported mixed results from its Phase II clinical trial of Arikayce, for the treatment…

Inflammatory diseasesInsmedPharmaceuticalRegulationRespiratory and PulmonaryUSA

Report: Global cystic fibrosis market value to treble by 2019

12-03-2014

The global cystic fibrosis market value in seven major countries will jump from $1.2 billion in 2013…

CanadaEuropeKalydecoMarkets & MarketingPharmaceuticalResearchRespiratory and PulmonaryUSAVertex

1 to 25 of 29 results

Back to top